Gottlieb floats third class of drugs idea—again

Share this article:
American Enterprise Institute resident fellow and former FDA deputy Scott Gottlieb told a Drug Information Association conference in June that there is “fairly strong” sentiment within the agency favoring creation of a third, behind-the-counter (BTC) drug class between Rx and OTC.

However, he said, some physicians have raised safety issues, questioning whether consumers should self-medicate with products that are only available by prescription, and expressing doubts that appropriate patient monitoring is possible without medical supervision. He said another motive for physicians' opposition might be the prospect of losing revenues generated by repeat office calls for monitoring.

“Before FDA would consider a product for re-classification to OTC, for example,” he said, “the agency must be assured that the product has a favorable adverse event profile, and that use of the product requires no special monitoring.”

He said that these same criteria, if applied to BTC switch, might rule out switching products used to treat BPH (benign prostatic hyperplasia), as good medical practice dictates that patient screening for prostate cancer be accomplished prior to going on medications.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.